AlzProtect pens Parexel brain disease pact using new Biotech division

purple brain
The pair will work together on a midstage test for progressive supranuclear palsy. (Raman Oza / Pixabay)

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy (PSP).

The Lille, France-based company will use Parexel for its PSP trial, which is a rare degenerative disease of the brain that causes serious problems with walking, balance and eye movements, using the CRO for work from protocol writing to the coordination of patient recruitment.

It will tap into Parexel’s new “Biotech” unit, a dedicated division launched in January to “support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology executives

“It was important for us to work with an internationally renowned partner covering the full range of needs for our first phase 2a clinical trial,” said Philippe Verwaerde, president and scientific director of AlzProtect.

“AlzProtect is committed to achieving Phase 2a results in complete confidence. With PAREXEL Biotech, we now have access to the expertise necessary to achieve this goal,” said Laurent Dupire, COO of AlzProtect.

“PAREXEL’S recently launched Biotech unit delivers innovative, customized offerings to the biotech community, building on our more than 20 years of experience in this area,” said Jim Anthony, global head of Biotech, Parexel.  

“Our collaboration with AlzProtect is a great example of how we can work together in a unique way, and we look forward to helping advance this important rare disease initiative.”

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.